Drug intelligence / Profile preview

MTX223

Development stage: Preclinical
Lead developer: Biodexa Pharmaceuticals
Administration: Injectable

Overview

MTX223 is a proprietary experimental large-molecule medicine developed by Janssen Pharmaceutica NV. It is being formulated as a long-acting injectable using Midatech Pharma PLC's Q-Sphera drug delivery technology. The collaboration between Midatech and Janssen aims to optimize the formulation of MTX223, with Janssen conducting in vivo studies to evaluate the new formulation.

Beyond the preview

Go deeper on MTX223.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTX223.

Explore the full profile